Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 231631 for:    ALL
Previous Study | Return to List | Next Study

Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma (Best Of)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified December 2016 by European Organisation for Research and Treatment of Cancer - EORTC
Sponsor:
Collaborator:
Swiss Group for Clinical Cancer Research
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier:
NCT02984410
First received: November 28, 2016
Last updated: December 5, 2016
Last verified: December 2016

November 28, 2016
December 5, 2016
March 2017
March 2020   (final data collection date for primary outcome measure)
Change in the MD Anderson Dysphagia Inventory (MDADI) score [ Time Frame: at 4.5, 6, 9 and 12 months after randomization ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma
Phase III Study Assessing The "Best of" Radiotherapy Compared to the "Best of" Surgery (Trans-oral Surgery (TOS)) in Patients With T1-T2, N0 Oropharyngeal Carcinoma

Oropharyngeal Squamous Cell Carcinoma (OPSCC) arises in the soft palate, tonsils, base of tongue, pharyngeal wall, and the vallecula. Most of the patients with early stage OPSCC are usually cured. Treatment of early stage OPSCC can be successfully achieved with primary surgery including neck dissection, as indicated, or with definitive radiotherapy. The current standard treatment for OPSCC is therefore based on either surgery and/or radiotherapy, both associated with comparable, high tumor control rates but with different side effects profiles and technical constraints.

In order to decrease the potential morbidity of surgery, transoral approaches have been developed within the last decades, including transoral robotic surgery (TORS), transoral laser microsurgery (TLM)or conventional transoral techniques. On the other hand, patients with head and neck cancer treated with IMRT experienced significant improvements in cause specific survival (CSS) compared with patients treated with non-IMRT techniques thus suggesting that IMRT may be beneficial in terms of patient's outcomes and toxicity profile. It is as yet unclear however, which one of the new techniques is superior to the other in terms of function preservation. Given that the functional outcome of most importance is swallowing function, the preservation of swallowing is thus of major importance.

The main objective of the study is to assess and compare the patient-reported swallowing function over the first year after randomization to either IMRT or TOS among patients with early stage OPSCC.

Eligible patients will be randomized 1 to 1 to radiotherapy (Arm 1) or surgery (Arm 2).

ARM 1: Radiotherapy

Intensity modulated radiation therapy (IMRT) with Simultaneous integrated boost (SIB) will be applied to all patients in this arm. PTV prescription to tumor and high risk areas will be delivered daily for 5 days per week to a total dose of 66-70Gy in 2 Gy/fraction over 6 weeks, elective/prophylactic mucosal and nodal areas will receive a total dose of 54.25- 54.45 Gy in 33-35 fractions of 1.55-1.65 Gy over 6 weeks.

ARM 2: Surgery

Trans-oral surgery (any trans-oral approach such as trans-oral laser microsurgery conventional trans-oral surgery (only for OPC of the tonsil) or trans-oral robotic surgery) will be applied to all patients in this arm.

A surgical margin is defined to be clear (R0), if found to be >/=3mm in the final specimen (except deep margin for tonsillar resection, that is either R1 or R0), is defined to be close, if 1-<3mm, and considered to be involved (R1), if <1mm in the final specimen. Clearly defined marginal biopsies are required for each TOS-technique. Trans-oral re-resections are required in case of R1 or close-margin to convert the patient to an R0-status.Postoperative RT or chemo-RT will be given within 5-6 weeks of surgery in case of positive.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Oropharyngeal Cancer
  • Radiation: Intensity-Modulated Radiation Therapy
  • Procedure: Trans Oral Surgery
  • Intensity-Modulated Radiation Therapy
    PTV prescription to tumor and high risk areas will be delivered daily for 5 days per week to a total dose of 66-70Gy in 2 Gy/fraction over 6 weeks, elective/prophylactic mucosal and nodal areas will receive a total dose of 54.25- 54.45 Gy in 33-35 fractions of 1.55-1.65 Gy over 6 weeks.
    Intervention: Radiation: Intensity-Modulated Radiation Therapy
  • Trans Oral Surgery

    The following surgical techniques are allowed:

    Transoral Robotic Surgery (TORS) Transoral Microsurgery (TLM) Conventional trans-oral Surgery (CTOS)

    Intervention: Procedure: Trans Oral Surgery
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
170
Not Provided
March 2020   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • OPSCC in one or more of the following sub-institutions: base of tongue, lateral pharyngeal wall, tonsil, glosso-tonsillar sulcus;
  • TNM stage I-II : T1 or T2 N0,M0
  • Within 2 weeks before randomization, assessed by a Multi-Disciplinary Team (MDT) composed of at least a head and neck/ENT surgeon, oncologist, radiologist, radiotherapist, and pathologist to be treatment naïve patient and suitable for either TOS or IMRT based on:
  • CT with contrast and/or MRI done within 4 weeks prior to randomization
  • Panendoscopy with assessment of trans-oral exposure for resection.
  • In case of suspicious adenopathy, Diffusion Weighted MRI must be performed
  • N0 defined as node <1cm in greatest diameter, if 1-1.3cm in greatest diameter according to DW MRI, > 1.3 cm in greatest diameter to be considered N1;
  • Age 18 and older;
  • ECOG Performance status ≤ 2;
  • Availability of biological material for HPV/p16 testing
  • Study information and Informed consent discussed by the surgeon and radio-oncologist and signed by the patient.
  • Within 2 weeks prior randomization:
  • Baseline MDADI score available;
  • Adequate bone marrow function as demonstrated by neutrophils count > 1,5 109 /L , platelets count > 75 109 /L, WBC≥ 3.0 109 /L;
  • Prothrombin time (PT) with an international normalized ratio (INR) ≤ 1.2
  • Partial thromboplastin time (PTT) ≤ 1.2 times ULN
  • Normal 12-lead ECG;
  • Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test
  • Patients of childbearing / reproductive potential should agree to use adequate birth control measures. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.

Exclusion Criteria:

  • Any previous anti-cancer therapy for HNSCC (chemo or radiotherapy or molecular targeted therapy);
  • Any active malignancy (other than non-melanoma skin cancer or localized cervical cancer or localized and presumed cured prostatic cancer) within the last 5 years with ongoing systemic treatment
  • Cancer in contact with the internal and/or external carotid artery
  • Extension of the cancer across the midline of the base-of-tongue
  • Involvement of >50% of the soft palate by cancer, requiring a reconstruction with a free flap or any other involvement of the soft palate requiring a reconstruction with a free flap judged by the surgeon
  • Cancer originating from the soft palate or posterior pharyngeal wall
  • Pre-existing dysphagia not related to the oropharyngeal cancer
  • Any psychological, cognitive, familial, sociological or geographical condition potentially hampering compliance with the study protocol, completion of patient reported measures and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Both
18 Years and older   (Adult, Senior)
No
Contact: Céline Demarez celine.demarez@eortc.be
Contact: General study e-mail address 1420@eortc.be
Not Provided
 
NCT02984410
EORTC-1420-HNCG-ROG
Not Provided
Not Provided
Not Provided
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
Swiss Group for Clinical Cancer Research
Study Chair: Christian Simon Centre Hospitalier Universitaire Vaudois
European Organisation for Research and Treatment of Cancer - EORTC
December 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP